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New Prodiginines
from a Ketosynthase Swap
The prodiginine antibiotics exhibit antitumor and im-
munosuppressive activity. In this issue of Chemis-
try & Biology, Reynolds and coworkers [1] demon-
strate that new prodiginines can be obtained by
substituting a FabH ketosynthase for the RedP keto-
synthase in the undecylprodiginine biosynthetic gene
cluster.
The prodiginines are a family of red-pigmented antibiot-
ics produced by Actinomycetes and other eubacteria
[2]. These compounds exhibit a broad range of activity
against bacteria, protozoa, and pathogenic fungi, but
they have not been used clinically because of their tox-
icity [2, 3]. Interest in the clinical development of pro-
diginine-like drugs has been stimulated by their novel
immunosuppressive activity, which functions by a dif-
ferent mechanism than either cyclosporine or FK506
[2], and by their potent apoptotic effects on cancer
cells [4]. A number of new prodiginine analogs with im-
proved therapeutic value have been prepared syntheti-
cally [2, 4]. The most thoroughly studied member of the
prodiginine family is undecylprodiginine (1), which is
produced by Streptomyces coelicolor A3(2) along with
the oxidatively cyclized analog, butyl-m-cycloheptyl-
prodiginine (2) (Figure 1). Labeling studies have shown
that undecylprodiginine is derived from one unit each
of proline, glycine, and serine and multiple units of ace-
tate via a convergent biosynthetic pathway that in-
volves the condensation of of 4-methoxy-2,2#-bipyr-
role-5-carboxaldehyde (3) with 2-undecylpyrrole (4)
(Figure 1) [5–7]. Sequencing of the S. coelicolor A3(2)
genome has revealed the entire red biosynthetic gene
cluster that is responsible for prodiginine production in
this organism [3]. Eight of the 23 genes in the cluster
have been proposed to play a role in the formation of
2-undecylpyrrole [3]. Three genes in the 2-undecylpyr-
role pathway, redP, redR, and redQ, exhibit homologies
to the ketoacyl acyl carrier protein (ACP) synthase
FabH (KASIII), the ketoacyl ACP synthase FabF (KASII),
and to ACPs, respectively [3]. FabH, FabF, and ACP are
components of the type II dissociated fatty acid syn-
thase (FAS) in Streptomyces, Escherichia coli, and
other bacteria [8–11]. The role of FabH in type II FAS
systems is to initiate fatty acid biosynthesis by catalyz-
ing the condensation of an acyl-CoA thioester with a
malonyl ACP [12], while FabF functions to extend the
fatty acid chain by catalyzing subsequent condensa-
tion reactions. The acyl group specificity of FabH ap-
pears to contribute to the type of fatty acids made by
an organism [13–15]. Because of the aforementioned
homologies, it has been postulated that RedP initiates
2-undecylpyrrole (4) biosynthesis by catalyzing the
condensation of acetyl CoA with malonyl RedQ [3]. The
resulting acetoacetyl thioester bound to RedQ is thenrved. DOI 10.1016/j.chembiol.2005.01.007
reduced to butyryl RedQ by the appropriate type II FAS
enzymes [3]. The FabF homolog RedR is proposed to
catalyze four additional elongation steps by using mal-
onyl RedQ, with complete FAS processing of the 3-keto
group occurring after each condensation. The resulting
dodecyl RedQ is thought to serve as the substrate for
an unusual polyketide synthase (PKS) encoded by redX
that uses a malonyl extender unit bound to an ACP do-
main in the redN gene product to produce a 3-ketomyri-
stoyl thioester. Additional enzymes encoded by the
prodiginine gene cluster then convert the 3-ketomyris-
toyl thioester into 2-undecylpyrrole (4) [3].
Since fatty acid biosynthesis and polyketide biosyn-
thesis share similar enzymology, the relationship be-
tween these two biosynthetic processes in polyketide-
producing organisms such as Streptomyces has been
the subject of active inquiry [9, 11, 16, 17]. The results
of recent studies have revealed that KASs can show
ACP specificities that allow these two processes to
function independently [16]. It has been found, for ex-
ample, that the FabH of Streptomyces only reacts with
FAS ACPs and does not recognize ACPs of type II PKSs
[16]. Consequently, the interaction of a FAS-like pro-
cess with a PKS should involve a specific set of KAS
enzymes as well as a dedicated ACP [17]. The presence
of FabH homologs in a number of polyketide biosyn-
thetic gene clusters [18, 19] is consistent with this ex-
pectation, as is the mechanism proposed for the forma-
tion of a dodecyl ACP in prodiginine biosynthesis. The
article by Reynolds et al. in this issue of Chemistry &
Biology [1] demonstrates that the interaction of FAS en-
zymes with the undecylprodiginine pathway is more
complex than anticipated. These investigators have
created a redP-deletion mutant of S. coelicolor and
have shown that it produces reduced levels of prodigi-
nines as well as two new analogs, 2-methylundecyl-
prodiginine and 2-methyldodecylprodiginine. Precursor
incorporation experiments with perdeuterated valine
indicate that these new analogs are produced from
3-methylbutyryl-CoA and isobutyryl-CoA starter units,
respectively. The 2-methylundecylprodiginine produced
in this mutant results from the extension of the leucine
catabolite 3-methylbutyryl CoA with five malonyl units,
while the 2-methyldodecylprodiginine is formed by ex-
tension of the valine metabolite isobutyryl CoA with six
malonyl units. Since the FabH of Streptomycetes has
been shown to exhibit a relaxed acyl group substrate
specificity compared to the E. coli FabH and is able to
use branched-chain CoA esters [13], the production of
these new alkyl prodiginines can be explained if the
priming of prodiginine biosynthesis in the redP mutant
is initiated by the endogenous S. coelicolor FabH. The
role of FabH was confirmed by introduction of a plas-
mid expressing the S. glaucescens FabH into the redP
mutant. The complemented mutant showed a nearly
4-fold increase in overall prodiginine production, while
the ratios of the various analogs were unchanged from
those of the mutant. Furthermore, introduction of a
plasmid expressing either RedP or the E. coli FabH into
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146Figure 1. Biosynthesis of Undecylprodiginine
and Butyl-m-Cycloheptylprodiginine from
4-Methoxy-2,2#-Bipyrrole-5-Carboxaldehyde
and 2-UndecylpyrroleSthe mutant reduced the levels of the new, branched
prodiginines relative to undecylprodiginine, as would
be expected.
An interesting feature of the FabH-dependent prodig-
inine pathway is that the straight-chain prodiginine
analogs predominate. In contrast, the fatty acids of
Streptomyces consist primarily of branched-chain com-
pounds [20]. This difference could be produced by
changes in the pool size of different acyl CoA esters as
the fermentation enters stationary phase and prodigi-
nine production begins. On the other hand, it might re-
sult from differences in the specificity of downstream
enzymes. For example, the fatty acid extension enzyme
FabF may prefer branched-chain acyl ACP substrates,
while RedR (a FabF homolog) may process straight-
chain acyl ACPs more efficiently. Additional studies will
1clearly be needed to elucidate the reasons for the ob-
served differences in product ratios between fatty acid
1biosynthesis and FabH-dependent undecylprodiginine
biosynthesis. If the ratio of straight-chain to branched-
1
chain prodiginines is governed by the specificity of
downstream enzymes, then the engineering of the pro- 1
diginine pathway to produce a preponderance of
1branched-chain analogs could prove to be challenging.
Nevertheless, the work of Reynolds et al. [1] is note-
1worthy since it provides an example of the deployment
of a FAS FabH to alter the outcome of a second- 1
ary metabolic pathway. This technique should be use-
ful for the production of new analogs of other natural 1
products.
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